Title : A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.

Pub. Date : 2011 Jul 1

PMID : 21586819






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Doxorubicin (DOX) can sensitize NSCLC cells to TRAIL-induced apoptosis, indicating the possibility of combination therapy. Doxorubicin TNF superfamily member 10 Homo sapiens
2 Doxorubicin (DOX) can sensitize NSCLC cells to TRAIL-induced apoptosis, indicating the possibility of combination therapy. Doxorubicin TNF superfamily member 10 Homo sapiens
3 Unfortunately, the therapeutic effect of a DOX and TRAIL combination is limited by multiple factors including the short serum half-life of TRAIL, poor compliance and application difficulty in the clinic, chronic DOX-induced cardiac toxicity, and the multidrug resistance (MDR) property of NSCLC cells. Doxorubicin TNF superfamily member 10 Homo sapiens
4 Unfortunately, the therapeutic effect of a DOX and TRAIL combination is limited by multiple factors including the short serum half-life of TRAIL, poor compliance and application difficulty in the clinic, chronic DOX-induced cardiac toxicity, and the multidrug resistance (MDR) property of NSCLC cells. Doxorubicin TNF superfamily member 10 Homo sapiens